Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. DSKYF.PINK

Daiichi Sankyo Company Limited (DSKYF PINK) stock market data APIs

$36.61 0(0%) as of July 25, 2024
Price chart is built with Anychart

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications caused by bone metastasis from tumors; Tarlige for treating neuropathic pain; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for COVID-19 infection, influenza infection, adsorbed cell culture-derived influenza (H5N1), measles/rubella infection, and mumps. The company has a development and sales collaboration with Merck & Co., Inc. and AstraZeneca UK Limited to develop anti-cancer drugs. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

Daiichi Sankyo Company Limited Financial Data Overview

36.61
36.61
-
36.61
36.45
23.3066-40.35
72 089 M
54.791
1 909 M
1 601 688 M
0.0106
0.239
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'DSKYF',
Type: 'Common Stock',
Name: 'Daiichi Sankyo Company Limited',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000JG7CY2',
ISIN: NULL,
CUSIP: '23380A109',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'March',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - General',
HomeCategory: 'ADR',
IsDelisted: false,
}

Daiichi Sankyo Company Limited Fundamental Data is available in our Financial Data APIs

  • Net Revenue 1 601 688 M
  • EBITDA 271 129 M
  • Earnings Per Share 0.67
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Daiichi Sankyo Company Limited Earnings via APIs

  • Latest Release 2024-07-31
  • EPS/Forecast 0.12

Get Daiichi Sankyo Company Limited End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Daiichi Sankyo Company Limited latest news via APIs

Arbitration Dispute Between Daiichi Sankyo and Seagen Ends

Daiichi Sankyo received approximately U.S. $47 million from Seagen as awarded by the arbitrator for attorneys’ fees and costs plus interest TOKYO & BASKING RIDGE, N.J., June 28, 2024--(BUSINESS WIR...

Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection

Merck MRK and its partner Daiichi Sankyo announced that the FDA has issued a complete response letter (“CRL”) to the biologics license application (BLA) seeking accelerated approval for patritumab...
Do you have any questions?
support@eodhistoricaldata.com